BNP Paribas Financial Markets
BCRX icon

BNP Paribas Financial Markets’s BioCryst Pharmaceuticals BCRX Stock Holding History

BNP Paribas Financial Markets’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Sell
1,302,257
-1,240,457
-49% -$9.63M 0.01% 1450
2025
Q4 		$19.8M Buy
2,542,714
+448,436
+21% +$3.24M 0.01% 1187
2025
Q3 		$15.9M Buy
2,094,278
+637,421
+44% +$5.31M 0.01% 1244
2025
Q2 		$13.1M Buy
1,456,857
+1,331,230
+1,060% +$12.4M 0.01% 1271
2025
Q1 		$942K Sell
125,627
-70,598
-36% -$569K ﹤0.01% 2828
2024
Q4 		$1.48M Sell
196,225
-300,559
-61% -$2.28M ﹤0.01% 2565
2024
Q3 		$3.78M Buy
496,784
+409,938
+472% +$3.12M ﹤0.01% 1660
2024
Q2 		$537K Sell
86,846
-80,936
-48% -$447K ﹤0.01% 2627
2024
Q1 		$852K Sell
167,782
-622,381
-79% -$3.5M ﹤0.01% 2582
2023
Q4 		$4.73M Buy
790,163
+247,195
+46% +$1.43M 0.01% 1442
2023
Q3 		$3.84M Buy
542,968
+327,226
+152% +$2.35M ﹤0.01% 1455
2023
Q2 		$1.52M Sell
215,742
-124,649
-37% -$1M ﹤0.01% 1927
2023
Q1 		$2.84M Buy
340,391
+183,818
+117% +$1.77M ﹤0.01% 1593
2022
Q4 		$1.8M Sell
156,573
-83,307
-35% -$1.04M ﹤0.01% 1829
2022
Q3 		$3.02M Buy
239,880
+199,198
+490% +$2.56M ﹤0.01% 1657
2022
Q2 		$430K Buy
40,682
+14,837
+57% +$153K ﹤0.01% 2738
2022
Q1 		$420K Sell
25,845
-40,011
-61% -$642K ﹤0.01% 2841
2021
Q4 		$912K Buy
65,856
+21,952
+50% +$291K ﹤0.01% 2652
2021
Q3 		$631K Buy
43,904
+27,151
+162% +$428K ﹤0.01% 2640
2021
Q2 		$265K Sell
16,753
-13,795
-45% -$187K ﹤0.01% 2788
2021
Q1 		$311K Buy
30,548
+11,781
+63% +$121K ﹤0.01% 2833
2020
Q4 		$140K Sell
18,767
-22,437
-54% -$116K ﹤0.01% 3055
2020
Q3 		$142K Buy
41,204
+5,467
+15% +$23.4K ﹤0.01% 2924
2020
Q2 		$170K Sell
35,737
-34,780
-49% -$139K ﹤0.01% 2558
2020
Q1 		$141K Buy
70,517
+53,338
+310% +$147K ﹤0.01% 3042
2019
Q4 		$59.3K Sell
17,179
-279
-2% -$702 ﹤0.01% 3548
2019
Q3 		$50K Buy
17,458
+5,197
+42% +$16.2K ﹤0.01% 3476
2019
Q2 		$46.5K Sell
12,261
-10,450
-46% -$62.9K ﹤0.01% 3463
2019
Q1 		$185K Buy
22,711
+22,674
+61,281% +$194K ﹤0.01% 2752
2018
Q4 		$299 Sell
37
-3,220
-99% -$25K ﹤0.01% 4050
2018
Q3 		$24.9K Hold
3,257
– – ﹤0.01% 3329
2018
Q2 		$18.7K Sell
3,257
-17,056
-84% -$93.9K ﹤0.01% 3523
2018
Q1 		$96.9K Sell
20,313
-143
-0.7% -$735 ﹤0.01% 3198
2017
Q4 		$100K Buy
20,456
+12,186
+147% +$59K ﹤0.01% 3304
2017
Q3 		$43.3K Sell
8,270
-584
-7% -$2.99K ﹤0.01% 3216
2017
Q2 		$49.2K Buy
8,854
+8,486
+2,306% +$51.7K ﹤0.01% 3202
2017
Q1 		$3.09K Sell
368
-3,744
-91% -$26K ﹤0.01% 3419
2016
Q4 		$26K Sell
4,112
-994
-19% -$5.17K ﹤0.01% 3080
2016
Q3 		$22.5K Buy
5,106
+2,194
+75% +$8.76K ﹤0.01% 2826
2016
Q2 		$8.27K Buy
+2,912
New +$9.04K ﹤0.01% 3003
2016
Q1 		– Sell
-14,796
Closed -$153K – 2699
2015
Q4 		$153K Sell
14,796
-198
-1% -$1.97K ﹤0.01% 2098
2015
Q3 		$171K Buy
14,994
+8,961
+149% +$120K ﹤0.01% 2064
2015
Q2 		$90.1K Buy
6,033
+4,383
+266% +$49.8K ﹤0.01% 2136
2015
Q1 		$14.9K Buy
+1,650
New +$17.1K ﹤0.01% 2525
2014
Q4 		– Sell
-4,191
Closed -$41K – 2105
2014
Q3 		$41K Buy
+4,191
New +$51.4K ﹤0.01% 2706

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

BNP Paribas Financial Markets's BCRX Position: Q1 2026 in Review

BNP Paribas Financial Markets reduced its BioCryst Pharmaceuticals (BCRX) stake by 49% in Q1 2026, selling an estimated $9.63M and leaving 1,302,257 shares worth $12.4M. The position accounts for 0.01% of the portfolio, ranked #1450.

BNP Paribas Financial Markets first reported a position in BCRX in Q3 2014 and has held it in 45 quarters since. The position peaked at $19.8M in Q4 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • BNP Paribas Financial Markets held 1,302,257 shares of BioCryst Pharmaceuticals worth $12.4M as of Q1 2026.
  • BNP Paribas Financial Markets sold 1,240,457 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $9.63M.
  • BioCryst Pharmaceuticals made up 0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #1450 holding.
  • BNP Paribas Financial Markets first reported a position in BioCryst Pharmaceuticals in Q3 2014 and has held it in 45 quarters since.
  • BNP Paribas Financial Markets's BioCryst Pharmaceuticals position peaked at $19.8M in Q4 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.